World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
71
Citations
17529
World Ranking
19998
National Ranking
111

Michael Dworzak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Dworzak sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 327 publications — 23rd percentile

23% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Dworzak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Dworzak sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 71 D-Index — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Dworzak is affiliated with the Medical University of Vienna in Austria. Their research spans key areas within medicine, particularly focusing on hematology and molecular biology. The scientist's work also covers public health, environmental and occupational health, genetics, and oncology, supporting a broad interdisciplinary approach.

The fields of study addressed in their publications include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these main fields, the subfields of study prominently represented in their research portfolio are:

  • Hematology
  • Molecular Biology
  • Public Health, Environmental and Occupational Health
  • Genetics
  • Oncology

Michael Dworzak's scientific topics emphasize a variety of hematological and oncological concerns. The main research topics involve:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Childhood Cancer Survivors' Quality of Life
  • Immunodeficiency and Autoimmune Disorders
  • Protein Degradation and Inhibitors
  • Neutropenia and Cancer Infections

The scientist has contributed a significant number of publications to several research venues, with a notable focus on hematology and oncology journals. Frequent publication venues are:

  • Blood
  • EJC Paediatric Oncology
  • Cancers
  • Haematologica
  • Pediatric Blood & Cancer

Collaboration is a prominent aspect of their career, with several frequent coauthors. These include:

  • Jan Starý
  • Barbara De Moerloose
  • Henrik Hasle
  • Franco Locatelli
  • Charlotte M. Niemeyer

Among the recent papers authored or coauthored by Michael Dworzak are:

  • The KMT2A recombinome of acute leukemias in 2023, published in Leukemia
  • Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden in 2021, published in Nature Communications
  • Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes in 2021, published in Nature Medicine
  • Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial in 2023, published in Journal of Clinical Oncology
  • Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG in 2021, published in Cancers

Best Publications

  • The MLL recombinome of acute leukemias in 2017

    C Meyer;T Burmeister;D Gröger;G Tsaur

  • Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.

    Ursula Creutzig;Marry M. van den Heuvel-Eibrink;Brenda Gibson;Michael N. Dworzak

  • The MLL recombinome of acute leukemias in 2013

    C. Meyer;J. Hofmann;T. Burmeister;D. Gröger

  • Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

    Martin Schrappe;Maria Grazia Valsecchi;Claus R. Bartram;André Schrauder

  • Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

    Brian V. Balgobind;Susana C. Raimondi;Susana C. Raimondi;Jochen Harbott;Martin Zimmermann

  • Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia

    Michael N. Dworzak;Gertraud Fröschl;Dieter Printz;Georg Mann

  • Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

    M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

  • Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.

    Marcin W. Wlodarski;Marcin W. Wlodarski;Shinsuke Hirabayashi;Victor Pastor;Jan Starý

  • Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

    Giuseppe Basso;Marinella Veltroni;Maria Grazia Valsecchi;Michael N. Dworzak

  • Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia

    C. Michel Zwaan;Edward A. Kolb;Dirk Reinhardt;Jonas Abrahamsson

  • Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98

    Ursula Creutzig;Martin Zimmermann;Dirk Reinhardt;Michael Dworzak

  • Treatment and prognostic impact of transient leukemia in neonates with Down syndrome

    Jan-Henning Klusmann;Ursula Creutzig;Martin Zimmermann;Michael Dworzak

  • Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98

    Christine von Neuhoff;Dirk Reinhardt;Annette Sander;Martin Zimmermann

  • Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

    Sarah Ebinger;Erbey Ziya Özdemir;Christoph Ziegenhain;Sebastian Tiedt

  • Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group

    Gertjan J. L. Kaspers;Martin Zimmermann;Dirk Reinhardt;Brenda E. S. Gibson

  • Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98

    Ursula Creutzig;Martin Zimmermann;Thomas Lehrnbecher;Norbert Graf

  • AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

    U Creutzig;D Reinhardt;S Diekamp;M Dworzak

  • High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

    Wolfgang Warsch;Karoline Kollmann;Eva Eckelhart;Sabine Fajmann

  • Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

    H Kovar;M Dworzak;S Strehl;E Schnell

  • Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

    Ursula Creutzig;Martin Zimmermann;Jean-Pierre Bourquin;Michael N. Dworzak

Frequent Co-Authors

Dirk Reinhardt
Dirk Reinhardt University of Duisburg-Essen
Henrik Hasle
Henrik Hasle Aarhus University Hospital
Helmut Gadner
Helmut Gadner St Anna Children's Hospital
Martin Zimmermann
Martin Zimmermann Hannover Medical School
Charlotte M. Niemeyer
Charlotte M. Niemeyer University of Freiburg
Oskar A. Haas
Oskar A. Haas Medical University of Vienna
Giuseppe Basso
Giuseppe Basso University of Padua
Marco Zecca
Marco Zecca University of Pavia
Thomas Lehrnbecher
Thomas Lehrnbecher Goethe University Frankfurt

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a medical career but want flexible study options, online programs can offer a convenient and often more affordable pathway. Beyond traditional medical school, many students pursue nursing or advanced practice roles through online education.

Aspiring nurse practitioners, for example, can take advantage of the cheapest np programs online to earn a graduate degree while balancing work and life commitments. Registered nurses aiming to further their careers often consider the cheapest rn to bsn online programs, allowing them to complete their BSN in a flexible and affordable manner.

Nurses interested in research or academic leadership might look into online phd programs in nursing, which prepare students for advanced scholarly and teaching positions. For those seeking maximum affordability, there are also great options among the cheapest rn to bsn online programs across the country.

These online degrees offer flexibility, accessibility, and a range of career pathways for individuals dedicated to advancing in the health care field.

Best Scientists Citing Michael Dworzak

Trending Scientists

Recently Published Articles